Integrated DNA Technologies (IDT), a leading comprehensive genomics solutions provider based in Coralville, announced that Demaris Mills has been appointed president of the company, succeeding Trey Martin, who was promoted to a new position in Genomic Medicine within Danaher, IDT’s parent company.
Ms. Mills has worked with Danaher companies for more than 12 years. She brings global experience in life sciences, genomics and diagnostics to her new role.
“I have admired IDT for many years, and I am thrilled and humbled to have this opportunity to lead such a storied and important company,” Ms. Mills said in a press release. “IDT is in an excellent position to build upon its core technologies in next generation sequencing (NGS), CRISPR, synthetic biology, and qPCR to deliver groundbreaking solutions that will best serve scientists in academic and commercial research, agriculture, medical diagnostics, and pharmaceutical development. This is an exciting time as IDT expands its products and service offerings to become the global leader in genomics applications that advance research and clinical care around the world.
Most recently, Ms. Mills served as president of Phenomenex. Prior to Phenomenex, she worked for Beckman Coulter Life Sciences and Leica Biosystems Consumables Business in a number of roles. She received her MBA from Harvard Business School and a bachelor’s degree in economics and French from Smith College in Massachusetts.
“I look forward to working with our customers, associates, and partners to further IDT’s single-minded commitment to offering innovative solutions and services that help advance the field of genomics research to improve the human condition,” she stated.
Mr. Martin’s promotion to Genomic Medicine comes just over three years after being appointed president in April 2018, following the acquisition of IDT by Danaher.
IDT works to develop, manufacture and market nucleic acid products for academic and commercial research, agriculture, medical diagnostics, and pharmaceutical development.